Rockstroh J, et al.: Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide, from a boosted protease inhibitor-based regimen

Zurück zur Übersicht

05.-08.10.2020 / HIV Drug Therapy – Glasgow